Tag: oral biologics and biosimilars market key players

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Oral Biologics & Biosimilars Market Size, Value And Growth Trajectory Through 2030

The oral biologics & biosimilars market has experienced substantial expansion in recent years. This market is set to increase from $9.37 billion in 2025 to $11.28 billion in 2026, registering a compound annual growth rate (CAGR) of 20.3%. The drivers behind its historical growth include the limited availability of oral biologics, the high cost of biologic therapies, a reliance on injectable formulations, the rising prevalence of chronic diseases, and the expanding networks of hospitals and retail pharmacies.

The oral biologics & biosimilars market size is anticipated to experience substantial growth in the upcoming years. It is projected to reach $24.69 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 21.6%. This expected expansion is driven by factors such as the progress in biosimilar and combination therapy development, the broadening of oral biologics pipelines, an increasing patient preference for oral medications, the rising use of digital adherence tools, and supportive government policies and reimbursement systems. Key trends in the forecast period include the growing acceptance of oral biologics and biosimilars for chronic diseases, an increase in targeted therapies for conditions like diabetes, arthritis, and cancer, the accelerated creation of monoclonal antibody-based oral treatments, the expansion of distribution channels through hospitals, retail outlets, and online pharmacies, and an emphasis on patient adherence and personalized treatment strategies.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=90720536&type=smp&name=Oral%20Biologics%20%26%20Biosimilars%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Oral Biologics & Biosimilars Market Industry Drivers: What’s Behind The Revenue Growth?

The increasing incidence of chronic illnesses is anticipated to fuel the expansion of the oral biologics and biosimilar market in the future. These enduring health conditions, which often advance gradually, include conditions like diabetes, cardiovascular diseases, and respiratory disorders. A significant factor contributing to this increase in chronic diseases is sedentary lifestyles, where extended periods of physical inactivity elevate the risk of obesity, heart disease, type 2 diabetes, and specific cancers. Oral biologics and biosimilars facilitate this trend by offering patients managing chronic conditions more accessible, economical, and convenient treatment alternatives. For example, data from January 2023, provided by the Centers for Disease Control and Prevention (CDC), a US-based federal agency, indicated that in 2023, 76.4% of U.S. adults (roughly 194 million individuals) reported having at least one chronic condition. The prevalence rates were 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Consequently, the growing prevalence of chronic diseases is a primary impetus for the expansion of the oral biologics and biosimilar market.

Oral Biologics & Biosimilars Market Segments: Where Is Growth Concentrated?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

3) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

4) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

#Oral Biologics & Biosimilars Market Growth Trends: What’s Shaping The Future Outlook?

Leading companies in the oral biologics & biosimilars market are concentrating on creating innovative solutions, such as customized smart capsule development services, to enhance the oral delivery of biologics, improve their bioavailability, and offer a patient-friendly administration method compared to traditional injectable formulations. These smart capsules incorporate advanced coatings, controlled-release matrices, or protective excipients to shield biologics from degradation within the gastrointestinal tract and optimize absorption in targeted intestinal regions, presenting a non-invasive alternative to injections and boosting patient adherence. For example, in December 2024, Lonza Group AG, a Switzerland-based contract development and manufacturing organization (CDMO), introduced a tailored service for smart capsule development, specifically to aid oral biologics development. This service provides customized formulation design, selection of protective excipients, and capsule engineering to ensure the stability and targeted release of biologics. It operates by improving the oral bioavailability of sensitive biomolecules while preserving their therapeutic efficacy. Its distinguishing characteristics include comprehensive support from the initial concept to preclinical testing, compatibility with various biologic modalities (proteins, peptides, nucleic acids), and scalable manufacturing solutions. Applications extend to the oral delivery of monoclonal antibodies, therapeutic peptides, and vaccines. The advantages include greater patient convenience, reduced dependence on injections, improved compliance, and expedited development timelines for oral biologic therapies.

Oral Biologics & Biosimilars Market Key Participants And Competitive Landscape

Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

View The Full Oral Biologics & Biosimilars Market Report:

https://thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Oral Biologics & Biosimilars Market Largest Region: Which Geography Holds The Biggest Share?

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Oral Biologics & Biosimilars Market Expansion Outlook: What Revenue Opportunities Lie Ahead?

The market for oral biologics and biosimilars has seen exponential expansion over recent years, climbing from $9.37 billion in 2025 to $11.28 billion in 2026—a compound annual growth rate (CAGR) of 20.3%. During the historic period, this growth was driven by several factors including the scarce supply of oral biologic options, the steep price of biologic treatments, a continued preference for injectable forms, rising rates of chronic illnesses, and the expansion of both hospital and retail pharmacy networks.

Over the coming years, the oral biologics and biosimilars market is anticipated to experience explosive expansion. By 2030, its value is projected to hit $24.69 billion, fueled by a compound annual growth rate of 21.6%. This projected growth is primarily driven by the advancement of biosimilars and combination therapies, a broadening pipeline of oral biologics, a growing preference among patients for oral drug formats, increased use of digital tools to support medication adherence, and stronger financial backing and reimbursement frameworks from governments. Key trends shaping this period include the increasing application of oral biologics and biosimilars for managing chronic illnesses, a surge in targeted therapeutic approaches for conditions like diabetes, arthritis, and cancer, heightened development of oral treatments based on monoclonal antibodies, the widening reach of hospital, retail, and online pharmacy channels, and a sharper focus on ensuring patient compliance and developing tailored treatment regimens.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Oral Biologics & Biosimilars Market Opportunity Drivers: What Is Creating New Revenue Potential?

The increasing occurrence of long-term illnesses is anticipated to boost the expansion of the oral biologics and biosimilars market moving forward. Chronic diseases are persistent medical conditions that tend to advance slowly, including diabetes, heart disease, and respiratory ailments like asthma. This uptick in chronic conditions is mainly fueled by sedentary habits, as extended periods of physical inactivity elevate the likelihood of obesity, heart problems, type 2 diabetes, and some forms of cancer. Oral biologics and biosimilars facilitate this transition by offering more reachable, economically viable, and easier treatment options for individuals managing ongoing health issues. For example, in January 2023, the Centers for Disease Control and Prevention (CDC), a federal agency in the United States, reported that 76.4% of American adults—about 194 million people—had at least one chronic condition in 2023, with rates of 59.5% among young adults, 78.4% among middle-aged adults, and 93.0% among older adults. As a result, the growing prevalence of chronic diseases is fueling the growth of the oral biologics and biosimilars market.

Oral Biologics & Biosimilars Market Segment Landscape: Which Areas Lead Market Development?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

3) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

4) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

Oral Biologics & Biosimilars Market Innovation Trends Driving Future Development

Key players in the oral biologics and biosimilars market are prioritizing the creation of advanced solutions, such as tailored smart capsule development services, to enhance the oral delivery of biologics, improve bioavailability, and provide a more patient-friendly alternative to conventional injectable formulations. These smart capsules incorporate sophisticated coatings, controlled-release matrices, or protective excipients that shield biologics from degradation within the gastrointestinal tract and facilitate absorption in specific intestinal regions, offering a non-invasive option that boosts patient adherence to treatment. For example, in December 2024, Lonza Group AG, a Swiss contract development and manufacturing organization (CDMO), unveiled a specialized service for smart capsule development, aimed at advancing oral biologics. This service includes personalized formulation design, careful selection of protective excipients, and capsule engineering to maintain biologic stability and targeted release; it operates by increasing the oral bioavailability of sensitive biomolecules while ensuring therapeutic effectiveness. Distinctive features encompass comprehensive support from concept through preclinical testing, adaptability to various biologic types (such as proteins, peptides, and nucleic acids), and scalable manufacturing options. Its applications extend to the oral delivery of monoclonal antibodies, therapeutic peptides, and vaccines. Benefits encompass enhanced patient convenience, decreased dependence on injections, better treatment compliance, and faster development timelines for oral biologic treatments.

Oral Biologics & Biosimilars Market Industry Leaders And Market Competition

Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Access The Complete Oral Biologics & Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Oral Biologics & Biosimilars Market Largest Region By Revenue And Market Share

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Size Of The Oral Biologics & Biosimilars Market Progress Through 2030?

The oral biologics & biosimilars market size has seen substantial growth recently. It is projected to increase from $9.37 billion in 2025 to $11.28 billion in 2026, achieving a compound annual growth rate (CAGR) of 20.3%. The expansion observed in prior periods was driven by the limited availability of oral biologics, the high cost associated with biologic therapies, a reliance on injectable formulations, the increasing prevalence of chronic diseases, and the growing networks of hospitals and retail pharmacies.

The oral biologics & biosimilars market size is projected to experience significant expansion in the coming years. Its value is anticipated to reach $24.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 21.6%. This forecasted growth is attributable to advancements in biosimilars and combination therapies, the enlargement of oral biologics pipelines, a greater patient inclination for oral drug delivery, increased use of digital adherence instruments, and enhanced government backing coupled with favorable reimbursement frameworks. Key trends expected during this period encompass the growing acceptance of oral biologics and biosimilars for managing chronic conditions, an increase in targeted therapeutic approaches for diabetes, arthritis, and cancer, the accelerated creation of monoclonal antibody-derived oral treatments, the broadening of distribution networks through hospitals, retail outlets, and online pharmacies, and a strong emphasis on ensuring patient compliance and tailoring treatment strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

What Influential Factors Are Boosting The Oral Biologics & Biosimilars Market Demand?

The increasing incidence of long-term health issues is anticipated to fuel expansion within the oral biologics and biosimilar market moving ahead. These enduring medical ailments, which generally develop gradually, include conditions like diabetes, cardiovascular diseases, and respiratory disorders. Sedentary lifestyles are a primary contributor to the increase in chronic diseases, given that extended periods of physical inactivity elevate the likelihood of developing obesity, heart disease, type 2 diabetes, and specific types of cancer. Oral biologics and biosimilars facilitate this trend by offering patients managing chronic conditions treatment alternatives that are more accessible, economical, and convenient. To illustrate, data from January 2023, provided by the Centers for Disease Control and Prevention (CDC), a US-based federal agency, showed that in 2023, 76.4% of U.S. adults (approximately 194 million people) indicated they had at least one chronic condition. The prevalence rates were 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Consequently, the growing incidence of chronic diseases is fueling the expansion of the oral biologics and biosimilar market.

How Does Segment Analysis Break Down The Oral Biologics & Biosimilars Market Structure?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

3) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

4) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

What Trends Are Affecting The Growth Of The Oral Biologics & Biosimilars Market?

Major companies operating in the oral biologics & biosimilars market are prioritizing the creation of innovative solutions, such as tailored smart capsule development services, to enhance the oral delivery of biologics, boost bioavailability, and provide patient-friendly administration in contrast to traditional injectable formulations. These smart capsules incorporate advanced coatings, controlled-release matrices, or protective excipients that shield biologics from degradation within the gastrointestinal tract and optimize absorption in specific intestinal regions, presenting a non-invasive alternative to injections and improving patient adherence. An example is Lonza Group AG, a Switzerland-based contract development and manufacturing organization (CDMO), which unveiled a tailored service for smart capsule development in December 2024, specifically supporting oral biologics development. This service encompasses customized formulation design, protective excipient selection, and precise capsule engineering to ensure the stability and targeted release of biologics; it operates by enhancing the oral bioavailability of sensitive biomolecules while maintaining therapeutic efficacy; unique attributes include comprehensive support from initial concept to preclinical testing, compatibility with various biologic modalities (such as proteins, peptides, and nucleic acids), and scalable manufacturing solutions; its applications span the oral delivery of monoclonal antibodies, therapeutic peptides, and vaccines; benefits comprise improved patient convenience, reduced reliance on injections, enhanced compliance, and accelerated development timelines for oral biologic therapies.

Who Are The Firms Contributing To The Oral Biologics & Biosimilars Market Ecosystem?

Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Access The Complete Oral Biologics & Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Which Regional Market Leads The Oral Biologics & Biosimilars Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Oral Biologics & Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Browse Through More Reports Similar to the Global Oral Biologics & Biosimilars Market 2026, By The Business Research Company

Dermatology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Oral Biologics & Biosimilars Market In 2026 And 2030?

The oral biologics & biosimilars market has seen substantial growth over recent years. Its valuation is set to rise from $9.37 billion in 2025 to $11.28 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 20.3%. This historical expansion can be attributed to several factors, including the limited availability of oral biologics, the high cost of biologic therapies, the prevailing reliance on injectable formulations, the increasing prevalence of chronic diseases, and the expanding networks of hospital and retail pharmacies.

The oral biologics & biosimilars market size is projected to experience substantial growth in the upcoming years. By 2030, its size is anticipated to reach $24.69 billion, expanding at a compound annual growth rate (CAGR) of 21.6%. This expansion during the projection period stems from factors such as the advancement of biosimilars and combination treatments, the broadening of oral biologics pipelines, a greater patient inclination towards oral drugs, the increased utilization of digital adherence tools, and improved government backing along with reimbursement frameworks. Key trends expected over this period encompass a surge in the uptake of oral biologics and biosimilars for long-term illnesses, an increase in precision therapies targeting conditions like diabetes, arthritis, and cancer, the accelerated creation of oral treatments utilizing monoclonal antibodies, the widening of distribution networks through hospitals, retail outlets, and online pharmacies, and an emphasis on patient compliance and tailored therapeutic approaches.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Which Strong Drivers Are Impacting The Oral Biologics & Biosimilars Market Growth?

The increasing occurrence of chronic illnesses is anticipated to drive the expansion of the oral biologics and biosimilar market in the future. These conditions are defined as persistent health issues that usually develop gradually, including conditions like diabetes, cardiovascular diseases, and respiratory disorders. Sedentary lifestyles are a major contributor to the increase in chronic diseases, given that extended periods of physical inactivity elevate the risk of obesity, heart disease, type 2 diabetes, and certain cancers. In this context, oral biologics and biosimilars facilitate this trend by offering more accessible, economical, and user-friendly treatment alternatives for individuals handling chronic conditions. As an illustration, data from January 2023, released by the Centers for Disease Control and Prevention (CDC), a US-based federal agency, showed that in 2023, 76.4% of U.S. adults (approximately 194 million people) indicated they had at least one chronic condition. The prevalence rates were 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Consequently, the growing incidence of chronic diseases is propelling the expansion of the oral biologics and biosimilar market.

What Segment Categories Shape The Oral Biologics & Biosimilars Market Segment Landscape?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

3) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

4) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

What Trends Are Influencing The Evolution Of The Oral Biologics & Biosimilars Market?

Leading companies within the oral biologics & biosimilars market are concentrating on developing innovative solutions, such as specialized smart capsule development services, to enhance the oral delivery of biologics, boost bioavailability, and provide a more patient-friendly administration method compared to traditional injectable formulations. These smart capsules are engineered with advanced coatings, controlled-release matrices, or protective excipients, which shield biologics from degradation in the gastrointestinal tract and optimize absorption in targeted intestinal regions, thereby offering a non-invasive alternative to injections and improving patient adherence. For example, in December 2024, Lonza Group AG, a Switzerland-based contract development and manufacturing organization (CDMO), launched a tailored service for smart capsule development, specifically aimed at supporting oral biologics development. This service comprises customized formulation design, selection of protective excipients, and capsule engineering to ensure the stability and targeted release of biologics. It operates by improving the oral bioavailability of sensitive biomolecules while maintaining therapeutic efficacy. Unique aspects encompass end-to-end support from initial concept to preclinical testing, compatibility with multiple biologic modalities (proteins, peptides, nucleic acids), and scalable manufacturing solutions. Applications extend to the oral delivery of monoclonal antibodies, therapeutic peptides, and vaccines. The benefits include improved patient convenience, reduced reliance on injections, enhanced compliance, and accelerated development timelines for oral biologic therapies.

Who Are The Companies Operating Across The Oral Biologics & Biosimilars Market Value Chain?

Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Get The Full Oral Biologics & Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Which Region Holds The Highest Market Share In The Oral Biologics & Biosimilars Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oral Biologics & Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Browse Through More Reports Similar to the Global Oral Biologics & Biosimilars Market 2026, By The Business Research Company

Dermatology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Oral Biologics & Biosimilars Market During The Forecast Period 2026–2030?

The oral biologics & biosimilars market size has seen substantial growth in recent years. It is anticipated to expand from $9.37 billion in 2025 to $11.28 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 20.3%. This historical growth can be linked to the restricted availability of oral biologics, the elevated cost of biologic therapies, a strong reliance on injectable formulations, the increasing prevalence of chronic diseases, and the expanding networks of hospitals and retail pharmacies.

The oral biologics & biosimilars market is projected for substantial growth in the upcoming years. It is expected to reach $24.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 21.6%. This expansion during the forecast period is driven by the advancement of biosimilars and combination therapies, the broadening of oral biologics pipelines, an increasing patient preference for oral medications, the rising adoption of digital adherence tools, and growing government support and reimbursement policies. Key trends for the forecast period include the increasing use of oral biologics and biosimilars for chronic diseases, growth in targeted therapies for conditions such as diabetes, arthritis, and cancer, the accelerating development of monoclonal antibody-based oral treatments, the expansion of distribution channels across hospitals, retail, and online pharmacies, and a strong focus on patient adherence and personalized treatment plans.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Which Economic Or Industry Drivers Are Impacting The Oral Biologics & Biosimilars Market?

The escalating incidence of chronic illnesses is anticipated to stimulate the expansion of the oral biologics and biosimilar market in the coming years. Chronic diseases are defined as persistent health conditions that typically advance slowly, encompassing ailments such as diabetes, cardiovascular diseases, and various respiratory disorders. The growth in chronic diseases is largely propelled by sedentary lifestyles, as sustained physical inactivity heightens the risk of obesity, heart conditions, type 2 diabetes, and certain types of cancer. Oral biologics and biosimilars facilitate this by providing more accessible, economical, and convenient treatment options for patients managing long-term conditions. For illustration, in January 2023, information from the Centers for Disease Control and Prevention (CDC), a U.S. federal agency, showed that in 2023, 76.4% of U.S. adults (approximately 194 million people) reported having at least one chronic condition, with reported rates of 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the increasing prevalence of chronic diseases is a primary driver for the growth of the oral biologics and biosimilar market.

What Market Segments Are Evaluated Within The Oral Biologics & Biosimilars Market?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

3) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

4) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

What Industry Trends Are Redefining The Oral Biologics & Biosimilars Market?

Major companies in the oral biologics & biosimilars market are concentrating on developing innovative solutions, such as tailored smart capsule development services, to enhance the oral delivery of biologics, improve bioavailability, and enable patient-friendly administration when compared to traditional injectable formulations. Smart capsules are engineered with advanced coatings, controlled-release matrices, or protective excipients that shield biologics from degradation in the gastrointestinal tract and optimize absorption in targeted intestinal regions, presenting a non-invasive alternative to injections and improving patient adherence. For instance, in December 2024, Lonza Group AG, a Switzerland-based contract development and manufacturing organization (CDMO), launched a customized service for smart capsule development, specifically supporting oral biologics development. This service includes customized formulation design, protective excipient selection, and capsule engineering to ensure biologic stability and targeted release; it functions by boosting the oral bioavailability of sensitive biomolecules while maintaining therapeutic efficacy. Unique aspects encompass end-to-end support from concept to preclinical testing, compatibility with multiple biologic modalities (proteins, peptides, nucleic acids), and scalable manufacturing solutions. Applications span the oral delivery of monoclonal antibodies, therapeutic peptides, and vaccines, with benefits including improved patient convenience, reduced reliance on injections, enhanced compliance, and accelerated development timelines for oral biologic therapies.

Who Are The Top Market Participants Influencing The Oral Biologics & Biosimilars Market?

Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Read the full oral biologics & biosimilars market report here:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

What Are The Top-Performing Regions Within The Oral Biologics & Biosimilars Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oral Biologics & Biosimilars Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6830&type=smp

Browse Through More Reports Similar to the Global Oral Biologics & Biosimilars Market 2026, By The Business Research Company

Dermatology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the oral biologics & biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Oral Biologics & Biosimilars Market in 2026, and what figure is it projected to hit by 2030?

The oral biologics & biosimilars market has seen substantial expansion in recent years. It is anticipated to increase from $9.37 billion in 2025 to $11.28 billion in 2026, achieving a compound annual growth rate (CAGR) of 20.3%. Historically, this growth can be linked to the restricted availability of oral biologics, the high expense of biologic treatments, the common reliance on injectable formulations, the rising incidence of chronic diseases, and the development of hospital and retail pharmacy networks.

The oral biologics & biosimilars market size is anticipated to undergo substantial growth in the next few years. It is projected to reach $24.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 21.6%. The expansion during the forecast period can be attributed to the development of biosimilars and combination therapies, the broadening of oral biologics pipelines, an increasing patient inclination towards oral medications, the rising adoption of digital adherence tools, and growing government support and reimbursement policies. Significant trends in the forecast period include the increasing uptake of oral biologics and biosimilars for chronic diseases, a surge in targeted therapies for diabetes, arthritis, and cancer, the accelerated development of monoclonal antibody-based oral treatments, the widening of distribution channels through hospital, retail, and online pharmacies, and an emphasis on patient adherence and personalized treatment plans.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Which Drivers Are Affecting Market Participation In The Oral Biologics & Biosimilars Market?

The increasing incidence of chronic diseases is anticipated to drive the expansion of the oral biologics and biosimilar market. These enduring medical conditions, such as diabetes, cardiovascular diseases, and respiratory disorders, characteristically advance slowly. A key contributor to the rise in chronic diseases is sedentary lifestyles, as prolonged physical inactivity escalates the risk of obesity, heart disease, type 2 diabetes, and certain cancers. Oral biologics and biosimilars address this need by providing more accessible, cost-effective, and convenient treatment options for patients managing chronic conditions. For example, in January 2023, the Centers for Disease Control and Prevention (CDC), a US federal agency, reported that in 2023, 76.4% of U.S. adults (approximately 194 million people) had at least one chronic condition. Prevalence rates were noted at 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the growing prevalence of chronic diseases is a significant driver for the oral biologics and biosimilar market.

What Segment Classifications Make Up The Oral Biologics & Biosimilars Market?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

3) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

4) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

Which Competitive Trends Are Impacting The Structure Of The Oral Biologics & Biosimilars Market?

Leading entities within the oral biologics & biosimilars market are dedicating efforts to devising cutting-edge solutions, including specialized smart capsule development services, aimed at advancing the oral administration of biologics, boosting their bioavailability, and facilitating more patient-friendly usage than conventional injectable formats. These smart capsules incorporate sophisticated coatings, regulated-release matrices, or protective excipients, which shield biologics from breakdown in the gastrointestinal tract and enhance absorption in specific intestinal areas, thereby providing a non-invasive option to injections and boosting patient compliance. A notable example is Lonza Group AG, a Switzerland-based contract development and manufacturing organization (CDMO), which introduced a customized service for smart capsule development in December 2024, specifically aiding oral biologics development. This service incorporates bespoke formulation design, selection of protective excipients, and advanced capsule engineering to guarantee the stability and precise release of biologics; its mechanism involves improving the oral bioavailability of delicate biomolecules while preserving their therapeutic effectiveness. Its distinctive attributes comprise comprehensive support from initial concept through preclinical testing, adaptability with diverse biologic modalities such as proteins, peptides, and nucleic acids, and readily scalable manufacturing options. The applications cover the oral delivery of monoclonal antibodies, therapeutic peptides, and vaccines; the advantages encompass greater patient comfort, diminished dependence on injections, better adherence, and faster development cycles for oral biologic treatments.

Which Major Industry Participants Are Leading The Oral Biologics & Biosimilars Market Growth?

Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Oral Biologics & Biosimilars Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oral Biologics & Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6830&type=smp

Browse Through More Reports Similar to the Global Oral Biologics & Biosimilars Market 2026, By The Business Research Company

Dermatology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Oral Biologics & Biosimilars Market?

The market size for oral biologics & biosimilars has seen substantial growth in the past few years. The size is projected to increase from $7.04 billion in 2024 to $8.69 billion in 2025, witnessing a compound annual growth rate (CAGR) of 23.5%. The notable growth during the historical period is attributed to the enhanced collaborations and partnerships among market participants for improved understanding, the rising necessity for immunology, amplified demand encouraged by the cost-efficient production process, an aging demographic, governmental initiatives, and the capacity to dictate high prices.

What Growth Rate Is Forecasted for the Oral Biologics & Biosimilars Market by 2029?

It is anticipated that the market size for oral biologics & biosimilars will witness a significant expansion in the approaching years, estimated to reach $19.13 billion by 2029 with a compound annual growth rate (CAGR) of 21.8%. The predicted surge during the forecast period can be traced back to several factors such as robust R&D efforts in the field of oral biologics, preference for pills over injections, the rise in unhealthy lifestyles, technological advancements, the convenience of using oral biologics, improved access to healthcare, broader reimbursement for biologics, the escalation in biosimilars, and the increasing prevalence of chronic conditions. Key market trends for the projected period comprise investments in the oral biologics market for potential high-profit margins, the transition towards biologics due to the growing rate of innovation in the sector, and the production of microneedle injectors-based medications to enhance bioavailability while negating side effects of the subcutaneous route.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Which Key Companies Are Shaping the Future of the Oral Biologics & Biosimilars Market?

Major companies operating in the oral biologics & biosimilars market include Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, ALK-Abelló, Aimmune Therapeutics Inc., VIVUS Inc, Materia Medica Holding, VECTOR-MEDICA, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals, Biocon, Dr.Reddy’s, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Which Factors Are Driving Demand in the Oral Biologics & Biosimilars Industry?

The increasing incidence of chronic illnesses like arthritis, asthma, and cancer is believed to be a major driving force behind the expansion of the oral biologics and biosimilar market. The growth of such illnesses can be attributed to factors such as long work hours, insufficient physical exercise, and poor dietary and drinking habits, and the use of biologics to treat these conditions is on the rise. Biologics assist the immune system in targeting cancer cells, supporting the body’s natural defenses in eliminating harmful cells. A United Nations article from a US-based intergovernmental organization forecasts that by 2030, chronic diseases will be responsible for 70% of all global deaths. It is also predicted that these diseases will account for nearly 60% of all global mortalities. Thus, the escalating incidence of these conditions is fuelling the development of the biologics and biosimilar market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=6830&type=smp

How Is the Oral Biologics & Biosimilars Market Segmented by Several Divisions?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Tharpies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Interleukin Inhibitors: IL-1 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors

3) By Tumor Necrosis Factor-Alpha Inhibitors: TNF-α Blockers, Monoclonal Antibodies Targeting TNF-α

4) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

5) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

6) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

What are the Emerging Market Trends Driving the Growth of the Oral Biologics & Biosimilars Industry?

The rise in production of new insulin biosimilars is an emerging trend that is gaining ground in the oral biologics and biosimilar market. Major players in the sector are investing in this area, producing biosimilars of insulin to increase their market presence. An example of this came in January 2023 when Amgen, a U.S. biotechnology firm, introduced Amjevita, a biosimilar to Humira, reflecting progress in insulin biosimilar development. Their goal is to reduce expenditures and enhance access to essential therapies. Amjevita offers a more cost-effective alternative for ailments such as arthritis and Crohn’s disease, making diabetes treatments with insulin biosimilars more economical and accessible. These advancements intensify competition and stimulate innovation in biologics. The company’s mission is to discover, develop, manufacture and provide innovative human therapeutics.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Which Regions Are Driving Growth in the Oral Biologics & Biosimilars Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2024. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6830

This Report Delivers Insight On:

1. How big is the oral biologics & biosimilars market, and how is it changing globally?

2. Who are the major companies in the oral biologics & biosimilars market, and how are they performing?

3. What are the key opportunities and risks in the oral biologics & biosimilars market right now?

4. Which products or customer segments are growing the most in the oral biologics & biosimilars market?

5. What factors are helping or slowing down the growth of the oral biologics & biosimilars market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the oral biologics & biosimilars industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What is the Projected CAGR for the Oral Biologics & Biosimilars Market Size from 2025 to 2034?

The market for oral biologics and biosimilars has seen a significant expansion in its size over the recent years. The market is projected to escalate from a worth of $7.04 billion in 2024 to $8.69 billion in 2025, navigating a compound annual growth rate (CAGR) of 23.5%. This substantial growth during the historic period is ascribed to factors such as enhanced collaborations and alliances among the market participants for superior insights, augmented requirement for immunology, rising demand catalysed by cost-effective manufacturing procedures, an aging population, initiatives by the government, and the capacity to set high prices.

Expectations are high for the oral biologics & biosimilars market, with projections of remarkable growth in the coming years. The market’s worth is estimated to reach $19.13 billion by 2029, growing at a compound annual growth rate (CAGR) of 21.8%. Factors contributing to this prospective growth involve vigorous research and development efforts for oral biologics, preference for pills over injections, unhealthy lifestyle adoption, technological advancements, oral biologics’ convenience, improved healthcare accessibility, biologics reimbursement, the upswing in biosimilars, and the growing occurrence of chronic diseases. During the forecast period, considerable trends encompass investing in the oral biologics market to leverage significant profit margins, transitioning to biologics with the field’s increasing innovation rate, and creating drugs based on microneedle injectors for heightened bioavailability and to counteract the side effects present in the subcutaneous route.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

What External and Internal Drivers Are Contributing to the Growth of theOral Biologics & Biosimilars Market?

The escalating incidence of chronic illnesses like arthritis, asthma, and cancer is anticipated to boost the expansion of the oral biologics and biosimilar market. Lengthy work hours, scarce physical exercise, and detrimental food and beverage habits increase the occurrence of these chronic diseases, leading to wider usage of biologics for their treatment. Biologics bolster the immune system’s response towards cancer cells, assisting inherent bodily defenses in eliminating harmful cells. A United Nations article from a US-based intergovernmental organization forecasts that by 2030, chronic diseases will be responsible for 70% of all global fatalities, and it’s projected to cause almost 60% of all deaths globally. Consequently, the swelling prevalence of chronic diseases is fostering the growth of the biologics and biosimilar market.

What Segment Types Define the Oral Biologics & Biosimilars Market Structure?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Tharpies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Interleukin Inhibitors: IL-1 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors

3) By Tumor Necrosis Factor-Alpha Inhibitors: TNF-? Blockers, Monoclonal Antibodies Targeting TNF-?

4) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

5) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

6) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=6830&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Oral Biologics & Biosimilars Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2024. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Oral Biologics & Biosimilars Market?

The emergence of fresh insulin biosimilars has been identified as a significant trend gaining traction in the oral biologics and biosimilar market. Pioneers in the oral biologics and biosimilar market are channeling their resources into the development of a biosimilar equivalent of insulin in an attempt to secure a larger market share. For instance, Amgen, a biotechnology organisation based in the US, launched Amjevita, a biosimilar to Humira in January 2023. The introduction of this product is parallel to advancements made in the domain of insulin biosimilars. The company’s objective is to reduce expenditure and enhance accessibility to essential treatments. Amjevita offers a cost-effective solution for conditions such as arthritis and Crohn’s disease and makes treatments for diabetes employing insulin biosimilars more affordable and approachable. These advancements are escalating competition and encouraging progress in biologics. The firm prioritises the discovery, production and delivery of cutting-edge human therapeutics.

View the full report here:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

What Is the Definition of the Oral Biologics & Biosimilars Market?

Biologics are drugs made from living cells using highly complex technology, while biosimilars are created to function similarly to biologics but are not identical to biologics. The oral biologics and biosimilars comprise biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer’s, multiple sclerosis, HIV or AIDS, and other serious conditions and are used to treat chronic diseases such as diabetes, arthritis, and cancer.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6830

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of theOral Biologics & Biosimilars Market?

The growth of the oral biologics and biosimilar market is anticipated to be driven by the increasing incidence of chronic diseases such as cancer, arthritis, and asthma. Long hours of work, a lack of physical exercise, along with poor dietary and lifestyle habits are major contributors to the spread of chronic diseases. Biologics, which boost the body’s natural immune response against cancer cells, are being used more for treating these chronic illnesses. A report from a U.S.-based intergovernmental organization under the United Nations projects that by 2030, chronic diseases are expected to be responsible for 70% of all deaths globally. In fact, nearly 60% of total mortality worldwide is predicted to be due to chronic diseases. Therefore, the expanding prevalence of chronic diseases is propelling the growth of the biologics and biosimilar market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

#What Growth Opportunities Will Drive the Oral Biologics & Biosimilars Market’s CAGR Through 2034?

The market size for oral biologics & biosimilars has seen a significant surge in growth in recent times, escalating from $7.04 billion in 2024 to an estimated $8.69 billion in 2025. This corresponds to a compound annual growth rate (CAGR) of 23.5%. Factors that contributed to this historic growth include heightened collaboration and partnerships among market participants for improved insights, the rising need for immunology, a boost in demand due to the cost-effectiveness of the manufacturing process, an aging population, initiatives put forth by governments, and the capacity to set high prices.

In the coming years, substantial expansion is anticipated in the oral biologics & biosimilars market, with projections predicting it to reach $19.13 billion in 2029, displaying a compound annual growth rate (CAGR) of 21.8%. This promising forecast is linked to numerous factors including rigorous R&D in the development of oral biologics, a growing preference for pills over injections, the adoption of unhealthy lifestyles, advancements in technology, the simplicity involved in using oral biologics, improved healthcare access, biologics reimbursement, increasing biosimilars, and a rising prevalence of chronic diseases. The forecast period also hints towards major trends, such as capitalizing on the oral biologics market for potentially lucrative profit margins, adapting to biologics due to an escalating innovation rate in the sector, and the creation of drugs based on microneedle injectors to elevate bioavailability and eradicate side effects associated with the subcutaneous route.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6830

What Key Market Trends and Innovations Are Shaping the Future of theOral Biologics & Biosimilars Industry?

A central trend emerging within the oral biologics and biosimilar market is the production of novel insulin biosimilars. Leading companies within the market are investing resources into developing a biosimilar version of insulin in a bid to seize a larger market share. For instance, January 2023 saw US-based biotech company, Amgen, launch Amjevita (which is a biosimilar to Humira), a vital step forward in the creation of insulin biosimilars. Their objective is to cut costs and enhance accessibility to essential treatments. The availability of Amjevita as a lower-cost alternative for conditions like arthritis and Crohn’s disease, together with insulin biosimilars for more cost-effective and accessible diabetes care is promoting competition and fostering innovation within the realm of biologics. The company’s core focus lies in the discovery, development, manufacture, and delivery of innovative human therapeutics.

Which Companies Are Leading the Charge in Expanding theOral Biologics & Biosimilars Market Growth?

Major companies operating in the oral biologics & biosimilars market include Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, ALK-Abelló, Aimmune Therapeutics Inc., VIVUS Inc, Materia Medica Holding, VECTOR-MEDICA, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals, Biocon, Dr.Reddy’s, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

How is the Global Oral Biologics & Biosimilars Market Segemented?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Tharpies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Interleukin Inhibitors: IL-1 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors

3) By Tumor Necrosis Factor-Alpha Inhibitors: TNF-a Blockers, Monoclonal Antibodies Targeting TNF-a

4) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

5) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

6) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=6830&type=smp

Which Geographics are Influencing the Growth of the Oral Biologics & Biosimilars Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2024. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Oral Biologics & Biosimilars Market 2025, By The Business Research Company:

Network Transformation Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/network-transformation-global-market-report

Gigabit Passive Optical Network Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gigabit-passive-optical-network-global-market-report

Network as a Service Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/network-as-a-service-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the oral biologics & biosimilars market grown over the years?

The market for oral biologics and biosimilars has seen a significant surge in recent times. Its size is predicted to rise from $7.04 billion in 2024 to $8.69 billion within a year, with a 23.5% compound annual growth rate. The historical growth of this market can be linked back to an increase in partnerships and collaborations among market participants for shared insight, amplified need for immunology, rising demand due to affordable production procedures, an aging demographic, government-led initiatives, and the power to demand premium pricing.

What Is the forecasted market size and growth rate for the oral biologics & biosimilars market?

The machine control system market is projected to see a swift expansion in the upcoming years, reaching a size of $9.36 billion by 2029 with a compound annual growth rate (CAGR) of 11.1%. This anticipated growth during the forecast period is largely due to increasing demand for unmanned vehicles, the integration of 5G technology, the growing emphasis on cybersecurity, the worldwide expansion of e-commerce, and the implementation of smart city initiatives. Key emerging trends for the forecasted period consist of the shift towards cloud-based machine control solutions, incorporation of advanced analytics, the rising use of hybrid and electric machines, and the uptake of 3D printing.

Get your oral biologics & biosimilars market report here!

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

What are the major factors driving growth in the oral biologics & biosimilars market?

The growth of the oral biologics and biosimilar market is anticipated to be driven by the escalating incidence of chronic diseases such as arthritis, asthma, and cancer. Factors like extended work hours, insufficient physical exercise, and unhealthy consumption habits contribute to the occurrence of these chronic illnesses. Biologics, due to their ability to boost the immune system against cancer cells, work effectively in treating these diseases and assist the body’s defenses in eliminating the cells causing the disease. A US-based intergovernmental organization reported in a United Nations article that chronic diseases are projected to constitute 70% of all global deaths by 2030. The expectation is that chronic disease will be responsible for nearly 60% of all death instances worldwide. As such, the surge in chronic diseases is a key factor propelling the growth of the biologics and biosimilar market.

What key areas define the segmentation of the global oral biologics & biosimilars Market?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Tharpies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Interleukin Inhibitors: IL-1 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors

3) By Tumor Necrosis Factor-Alpha Inhibitors: TNF-a Blockers, Monoclonal Antibodies Targeting TNF-a

4) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

5) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

6) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

What are the top market players propelling the growth of the oral biologics & biosimilars industry?

Major companies operating in the oral biologics & biosimilars market include Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, ALK-Abelló, Aimmune Therapeutics Inc., VIVUS Inc, Materia Medica Holding, VECTOR-MEDICA, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals, Biocon, Dr.Reddy’s, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

What are the key trends shaping the future of the oral biologics & biosimilars market?

The development of innovative insulin biosimilars is a significant growing trend in the oral biologics and biosimilar market. To grab a share of the market, key industry participants are concentrating their investments on developing biosimilar versions of insulin. For example, in January 2023, Amgen, a biotech company based in the United States, made significant headway in producing insulin biosimilars when they introduced Amjevita, a biosimilar to Humira. The aim of these advancements is to reduce costs and enhance the availability of essential remedies. Amjevita serves as a more affordable treatment alternative for diseases like arthritis and Crohn’s disease, making insulin biosimilars a more cost-effective and accessible treatment for diabetes. These strides are fueling competition and encouraging creativity in biotherapeutics. The corporation remains committed to the discovery, development, production, and distribution of innovative human therapeutics.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6830

What regions are dominating the oral biologics & biosimilars market growth?

North America was the largest region in the oral biologics and biosimilar drugs market in 2024. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Vaccines Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Diuretics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report

Hematology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: